Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
TherapeuticsMD, Inc. (TXMD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
3Distinct source URLs
9High confidence
0.794Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
TherapeuticsMD, Inc. Suppliers
Ticker
Name
Confidence
Evidence
COSETTE-PHARMACEUTICALS-INC
COSETTE-PHARMACEUTICALS-INC
85%
including as a result of Mayne Pharma Group’s potential sale to Cosette Pharmaceuticals, Inc.
of the net working capital allowance for returns. In August 2024, the Company received information from Mayne Pharma pertaining to the net working capital allowance for returns that differs significa…
Reciprocal relationship from ORANY graph: Reciprocal relationship from TXMD graph: of the net working capital allowance for returns. In August 2024, the Company received information from Mayne Pharma…
TherapeuticsMD, Inc. Customers
Ticker
Name
Confidence
Evidence
MAYNE-PHARMA
MAYNE-PHARMA
92%
The rant of the licenses under the Mayne License Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition of ne…
KNIGHT-THERAPEUTICS-INC
KNIGHT-THERAPEUTICS-INC
90%
In July 2018, we entered into a license and supply agreement (the "Knight License Agreement") with Knight Therapeutics Inc. ("Knight") pursuant to which we granted Knight an exclusive license to comm…
THERAMEX-HQ-UK-LIMITED
THERAMEX-HQ-UK-LIMITED
90%
In June 2019, we entered into an exclusive license and supply agreement (the "Theramex License Agreement") with Theramex HQ UK Limited ("Theramex") to commercialize IMVEXXY and BIJUVA outside of the …
MAYNE-PHARMA-GROUP
MAYNE-PHARMA-GROUP
80%
If Mayne Pharma's sales of Licensed Products grow more slowly than expected or decline, including as a result of Mayne Pharma Group's potential sale to Cosette Pharmaceuticals, Inc.
Reciprocal relationship from ORANY graph: Reciprocal relationship from TXMD graph: al product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-controlled,…
al product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy f…
CATALENT-PHARMA-SOLUTIONS-LLC
CATALENT-PHARMA-SOLUTIONS-LLC
62%
ir opinion that accompanies our audited consolidated financial statements as of and for the year ended December 31, 2025, indicating such. As of December 31, 2025, we had $7.5 million in cash and cas…
TEVA
Teva Pharmaceutical Industries Limited
62%
Reciprocal relationship from TEVA graph: Reciprocal relationship from TXMD graph: al product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-controlled, …
TEVA-PHARMACEUTICALS-USA-INC
TEVA-PHARMACEUTICALS-USA-INC
62%
al product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy f…
TherapeuticsMD, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TXMD-DEBT-13175
Warrants outstanding: 6534687
90%
xbrl warrant detail from xbrl 2023-12-31.
TXMD-DEBT-13176
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2012-12-31.
TXMD-DEBT
Debt stack $93.6M
90%
Market cache reports total debt of $93.6M.
TherapeuticsMD, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for TherapeuticsMD, Inc..
TherapeuticsMD, Inc. Ownership
Holder
Name
Confidence
Evidence
TXMD-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP
Rubric Capital Management LP
90%
13F overlay lists Rubric Capital Management LP as top holder; 51 tracked holders.
TherapeuticsMD, Inc. Extended Supply Chain Network
